

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Patent Application Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10/21/02 Signature: Denise Camerato
(Denise Camerato)

Docket No.: FGTI-P02-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Arthur L. Holden

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: October 21, 2003

Art Unit: N/A

For: **GENETIC PROFILING AND BANKING
SYSTEM AND METHOD**

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.


Those patent(s) or publication(s) which are marked with an asterisk (*) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application number 09/425085, filed October 22, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. FGTI-P02-004.

Dated: October 21, 2003

Respectfully submitted,

By _____
Edward J. Kelly
Registration No.: 38,936
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	2	Application Number	Not Yet Assigned
				Filing Date	October 21, 2003
				First Named Inventor	Arthur L. Holden
				Art Unit	
				Examiner Name	
				Attorney Docket Number	FGTI-P02-004

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AA**	US-5924074	07/1999	Evans		
AB**	US-5897989	04/1999	James E. Beecham		
AC**	US-4683195	07/1987	Mullis, et al.		
AD**	US-5050613	09/1991	Newman, et al.		
AE**	US-5523208	06/1996	Kohler, et al.		
AF**	US-5834181	11/1998	Anthony P. Shuber		
AG**	US-5876926	03/1999	James E. Beechman		
AH**	US-5920871	07/1999	Macri, et al.		
AI**	US-5941947	08/1999	Brown, et al.		
AJ**	US-5993387	11/1999	Moore, et al.		
AK**	US-6253203	06/2001	O'Flaherty, et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
BA**	WO-97/31327		08-28-1997		
BB**	EA-0913758		05-06-1999		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CA**	Pulst, S.M., 1999 Neurol., Vol. 56, No. 6, "Genetic Linkage Analysis", pp. 667-672				
CB**	Ballantyne, et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Molecular Markers for Atherosclerosis", pp. 353-356				
CC**	Marian, A.J. 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic Markers: Genes Involved in Human Hypertension", pp. 341-345				
CD**	Marian, A.J. 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic Markerts: Genes Involved in Atherosclerosis", pp. 333-339				
CE**	Hallman, D.M., et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Molecular and Genetic Approaches to the Study of Cardiovascular Disease##", pp. 325-331				
CF**	Ballantyne, et al., 1997 J. Cardiovasc. Risk, Vol. 4, No. 5-6, "Genetic and Molecular Markers for Vascular Disease", pp. 321-323				
CG**	Zehbe, et al., 1999 Lancet, Vol. 354 (9174), "Condon 72 Polymorphism of p53 and Its Association with Cervical Cancer", pp. 218-219				
CH**	Hakansson, et al., 1997 Am. J. Hum. Genet., Vol. 60, No. 5, "Moderate Frequency of BRCA1 and BRCA2 Germ-Line Mutations in Scandinavian Familial Breast Cancer," pp. 1068-1078				
CI**	Vaidya, et al., 1999 Lancet, Vol. 354 (9180), "Cytotoxic T Lymphocyte Antigen-4 (CTLA04) Gene				

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	October 21, 2003
				First Named Inventor	Arthur L. Holden
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	FGTI-P02-004

		Polymorphism Confers Susceptibility to Thyroid Associated Orbitopathy", pp. 743-744	
CJ**	Liao, et al., 1999 Angiology, Vol. 50, No. 8, "A Missense Mutation of the Nitric Oxide Synthase (eNOS) Gene (Clu298Asp) in Five Patients with Coronary Arter Disease", pp. 671-676		
CK**	Rust, et al., 1999 Nat. Genet. Vol. 22, No. 4, "Tangier Disease is Caused by Mutations in the Gene Encoding ATP-Binding Cassette Transporter 1", pp. 352-355		
CL**	Brooks-Wilson, 1999 Nat. Genet., Vol. 22, No. 4, "Mutations in ABC1 Tangier Disease and Familial High-Density Lipoprotein Deficiency", pp. 336-345		
CM**	Ligers, et al., 1999 Neuroimmunol., Vol. 97-102, "The CTLA-4 Gene is Associated with Multiple Sclerosis", pp. 182-190		
CN**	Shinar, et al., 1998 J. Mol. Neurosci., Vol. 11, No. 3, "Analysis of Allelic Association Between D6S461 Marker and Multiple Sclerosis in Ashkenazi and Iraqi Jewish Patients", pp. 265-269		
CO**	Schutte, et al., 1999 Am. J. Med. Genet., Vol. 84, No. 2, "Microdeletions at Chromosome Bands 1q32-q41 As A Cause of Van der Woude Syndrome", pp. 145-150		
CP**	Aita, et al., 1999 Am. J. Hum. Genet., Vol. 64, No. 1, "A Comprehensive Linkage Analysis of Chromosome 21q22 Supports Prior Evidence for A Putative Bipolar Affective Disorder Locus", pp. 210-217		
CQ**	Campbell, et al., 1999 Mol. Psychiatry, Vol. 4, No. 1, "Association Between A Marker in the UCP-2/UCP-3 Gene Cluster and Genetic Susceptibility to Anorexia Nervosa", pp. 68-70		
CR**	Scacchi, et al., 1999 Neurosci. Lett., Vol. 259, No. 1, "Plasma Levels of Apolipoprotein E and Genetic Markers in Elderly Patients with Alzheimer's Disease", pp. 33-36		
CS**	Kruger, et al., 1999 Ann. Neurol., Vol. 45, No. 5, "Increased Susceptibility to Sporadic Parkinson's Disease By A Certain Combined a-Synuclein/Apolipoprotein E Genotype", pp. 611-617		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with a double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------